QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=F814328285108F7A4EA0DA28CFE696D7;jsessionid=502E776C630F24248151AAEED05D5B46;jsessionid=3D6E4177C1A2C936A25F58E22CF119FE;jsessionid=345F3C3E31C12C444C4BFB6C7444F45F;jsessionid=BD9211D0409253AA8F0D3B430F1ADC06;jsessionid=FA979FF6DE873EBD7E5AC2E0DD2DEB1A;jsessionid=E1BB80C09086475ADB27119A3CDD32ED;jsessionid=4043DD0DD7500E2D9DCA95203B99031C;jsessionid=8096AA3D0A7239BC68D0631183BF77A3;jsessionid=8C6CB774AF28B38BFACDA266B4A04CEF;jsessionid=265D026E29DD36BD7BD3F23B2B884FFF;jsessionid=515A8F1CD1C2293C63980C62BFD91ECD (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. The polyglutamine protein ATXN2: from its molecular functions to its involvement in disease.
3. Clinical features, disease progression, and nuclear imaging in ATXN2-related parkinsonism in a longi…
4. ATXN2 is a target of N-terminal proteolysis.
5. A Case of Coexistent Spinocerebellar Ataxia Type 2 and Primary Progressive Multiple Sclerosis-Coinci…

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=F814328285108F7A4EA0DA28CFE696D7;jsessionid=502E776C630F24248151AAEED05D5B46;jsessionid=3D6E4177C1A2C936A25F58E22CF119FE;jsessionid=345F3C3E31C12C444C4BFB6C7444F45F;jsessionid=BD9211D0409253AA8F0D3B430F1ADC06;jsessionid=FA979FF6DE873EBD7E5AC2E0DD2DEB1A;jsessionid=E1BB80C09086475ADB27119A3CDD32ED;jsessionid=4043DD0DD7500E2D9DCA95203B99031C;jsessionid=8096AA3D0A7239BC68D0631183BF77A3;jsessionid=8C6CB774AF28B38BFACDA266B4A04CEF;jsessionid=265D026E29DD36BD7BD3F23B2B884FFF;jsessionid=515A8F1CD1C2293C63980C62BFD91ECD